US 12,006,530 B2
Streptococcal proteases
Ulrich Von Pawel-Rammingen, Sävar (SE); and Christian Spoerry, Umeå (SE)
Assigned to Genovis AB, Lund (SE)
Appl. No. 16/075,059
Filed by GENOVIS AB, Lund (SE)
PCT Filed Feb. 3, 2017, PCT No. PCT/EP2017/052463
§ 371(c)(1), (2) Date Aug. 2, 2018,
PCT Pub. No. WO2017/134274, PCT Pub. Date Aug. 10, 2017.
Claims priority of application No. 1630021-2 (SE), filed on Feb. 4, 2016.
Prior Publication US 2019/0345533 A1, Nov. 14, 2019
Int. Cl. A61K 39/09 (2006.01); C12N 9/64 (2006.01); C12Q 1/37 (2006.01); G01N 33/68 (2006.01)
CPC C12Q 1/37 (2013.01) [C12N 9/641 (2013.01); G01N 33/6854 (2013.01)] 9 Claims
 
1. An in vitro method for the cleavage of human IgG1, the method comprising contacting human IgG1 with a purified polypeptide in vitro, wherein the purified polypeptide comprises:
(a) the amino acid sequence of SEQ ID NO: 3;
(b) a variant thereof having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 and having human IgG1 cysteine protease activity; or
(c) a fragment thereof of either (a) or (b), having human IgG1 cysteine protease activity.